[go: up one dir, main page]

WO2024178329A3 - Mutant ara h 2 and ara h 6 proteins and uses thereof - Google Patents

Mutant ara h 2 and ara h 6 proteins and uses thereof Download PDF

Info

Publication number
WO2024178329A3
WO2024178329A3 PCT/US2024/017072 US2024017072W WO2024178329A3 WO 2024178329 A3 WO2024178329 A3 WO 2024178329A3 US 2024017072 W US2024017072 W US 2024017072W WO 2024178329 A3 WO2024178329 A3 WO 2024178329A3
Authority
WO
WIPO (PCT)
Prior art keywords
ara
proteins
mutant
immunotherapy
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/017072
Other languages
French (fr)
Other versions
WO2024178329A2 (en
Inventor
Geoffrey A. MUELLER
Lars C. Pedersen
Jungki Min
Sarita PATIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
US Department of Health and Human Services
Original Assignee
General Hospital Corp
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, US Department of Health and Human Services filed Critical General Hospital Corp
Priority to EP24716910.5A priority Critical patent/EP4669657A2/en
Priority to AU2024224738A priority patent/AU2024224738A1/en
Publication of WO2024178329A2 publication Critical patent/WO2024178329A2/en
Publication of WO2024178329A3 publication Critical patent/WO2024178329A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8262—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield involving plant development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Provided herein are hypoallergenic mutant Ara h proteins, including Ara h 2 and Ara h 6, and uses thereof in treating allergic or anaphylactic responses to peanut allergens, immunotherapy and diagnostics.
PCT/US2024/017072 2023-02-23 2024-02-23 Mutant ara h 2 and ara h 6 proteins and uses thereof Ceased WO2024178329A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP24716910.5A EP4669657A2 (en) 2023-02-23 2024-02-23 Mutated ARA H 2 and ARA H 6 proteins and uses thereof
AU2024224738A AU2024224738A1 (en) 2023-02-23 2024-02-23 Mutant ara h 2 and ara h 6 proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363486570P 2023-02-23 2023-02-23
US63/486,570 2023-02-23

Publications (2)

Publication Number Publication Date
WO2024178329A2 WO2024178329A2 (en) 2024-08-29
WO2024178329A3 true WO2024178329A3 (en) 2024-09-26

Family

ID=90718848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/017072 Ceased WO2024178329A2 (en) 2023-02-23 2024-02-23 Mutant ara h 2 and ara h 6 proteins and uses thereof

Country Status (3)

Country Link
EP (1) EP4669657A2 (en)
AU (1) AU2024224738A1 (en)
WO (1) WO2024178329A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171268A1 (en) * 2012-05-15 2013-11-21 Biomay Ag Allergen variants
WO2023012652A2 (en) * 2021-08-03 2023-02-09 Ukko Inc. Hypoallergenic peanut allergens, production and use thereof
WO2023060151A1 (en) * 2021-10-06 2023-04-13 Vanderbilt University Peanut allergy epitope

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171268A1 (en) * 2012-05-15 2013-11-21 Biomay Ag Allergen variants
WO2023012652A2 (en) * 2021-08-03 2023-02-09 Ukko Inc. Hypoallergenic peanut allergens, production and use thereof
WO2023060151A1 (en) * 2021-10-06 2023-04-13 Vanderbilt University Peanut allergy epitope

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUNGKI MIN ET AL: "Design of an Ara h 2 hypoallergen from conformational epitopes", CLINICAL & EXPERIMENTAL ALLERGY, WILEY INTERSCIENCE, UK, vol. 54, no. 1, 2 January 2024 (2024-01-02), pages 46 - 55, XP072570250, ISSN: 0954-7894, DOI: 10.1111/CEA.14433 *
KING NINA ET AL: "Allergenic characteristics of a modified peanut allergen", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 49, no. 10, 1 October 2005 (2005-10-01), DE, pages 963 - 971, XP093173400, ISSN: 1613-4125, DOI: 10.1002/mnfr.200500073 *

Also Published As

Publication number Publication date
EP4669657A2 (en) 2025-12-31
WO2024178329A2 (en) 2024-08-29
AU2024224738A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
DK1272213T3 (en) Microbial delivery system
AU2003273171A1 (en) Immunomodulatory compounds and methods of use thereof
ATE527276T1 (en) PROTEINS THAT EFFECT ALTERED IMMUNOGENIC RESPONSES AND METHODS FOR THE PRODUCTION AND USE THEREOF
WO2004106486A3 (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
ATE452195T1 (en) PROTEASE MUTANTS WITH REDUCED ALLERGENIC EFFECT IN HUMANS AND METHODS FOR DESIGNING, IDENTIFYING AND PRODUCING THESE PROTEASES
WO2004090539A3 (en) Methods of determining efficacy of treatments of inflammatory diseases of the bowel
WO2024178329A3 (en) Mutant ara h 2 and ara h 6 proteins and uses thereof
EP1967206A3 (en) Anti-IgE vaccines
WO2002083879A3 (en) Immunotherapy based on dendritic cells
ATE466585T1 (en) PREPARATIONS OF GRAM-POSITIVE BACTERIA FOR THE TREATMENT OF DISEASES WITH IMMUNE DEFREGULATION
WO2022182872A3 (en) Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2004044155A3 (en) MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
AU2003269413A1 (en) Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2023012652A3 (en) Hypoallergenic peanut allergens, production and use thereof
EP2392674A3 (en) Cellular biomarker antioxidant assay and uses thereof
WO2024102700A3 (en) Compositions and methods for treating and suppressing allergic responses
Muszynski The relationship between demographic/situational factors, cognitive/affective variables, and needs and time to completion of the doctoral program in psychology.
WO2006058359A3 (en) Protein allergen derivatives
WO2024220398A3 (en) Compositions and methods for neutralizing antigens
AU2003297294A1 (en) Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
WO2006014907A3 (en) Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders
HK40112861A (en) Hypoallergenic peanut allergens, production and use thereof
WO2002022679A3 (en) Variants of phleum pratense allergenic proteins
AU2003208817A1 (en) Method for producing hypoallergenic major birch pollen allergens rbet v 1
TAICO et al. THE GUT MICROBIOME AND CROSS-REACTIVITY OF FOOD ALLERGENS: CURRENT UNDERSTANDING, INSIGHTS, AND FUTURE DIRECTIONS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024224738

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024224738

Country of ref document: AU

Date of ref document: 20240223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024716910

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24716910

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024716910

Country of ref document: EP

Effective date: 20250923

ENP Entry into the national phase

Ref document number: 2024716910

Country of ref document: EP

Effective date: 20250923